Hormone solutions for men and women.

Lawley Pharmaceuticals specializes in the niche area of providing pure testosterone and progesterone pharmaceutical grade creams for use in men and women.

The human endocrine system is a sophisticated, finely balanced and interactive blend of naturally produced chemicals that we call hormones. An excess or a deficiency of any particular hormone can create a domino effect that may have a profound impact on the way our body functions, how we feel, how we act and our overall quality of life.

We believe that the body naturally provides the hormones that are best suited to its needs, and that the use of synthetic hormones runs counter to this principle.

Our philosophy centres on the use of body-identical hormones.

Founded in 1995 and privately owned, Lawley Pharmaceuticals has become a world leader in research and development of topical hormone creams with our focus mostly on the hormone testosterone.

We work in collaboration with our manufacturing partners Perrigo Australia whose world class manufacturing facility is equipped with state-of-the-art equipment and operates to the strict international codes of Good Manufacturing Practice.

Lawley provides the hormone solutions for managing many patient conditions including the next generation low dose testosterone option for men - scrotal application - and the only commercially available testosterone product specifically for use in women.

Lawley Pharmaceuticals Head Office

Menopause specialists warn against dangers of “bioidentical hormones” Menopause specialists warn against dangers of “bioidentical hormones”

On Monday 15th July 2019 in a comprehensive interview on the Life Matters program (ABC Radio National) two of Australia’s premier menopause specialists, Dr Elizabeth Farrell and … Continue reading

BBC Menopause and testosterone replacement therapy BBC Menopause and testosterone replacement therapy

Over 900 specialist menopause physicians from around the world attended The European Menopause and Andropause Society conference held in Berlin on 15-17th May 2019. Numerous … Continue reading

Hypoactive Sexual Desire Disorder (HSDD) re-defined Hypoactive Sexual Desire Disorder (HSDD) re-defined

In late 2018 the World Health Organisation (WHO) released an update to The International Classification of Disease (ICD). ICD is a system of medical coding created … Continue reading